CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Developmen... (multiple myeloma a population known to b...)

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

Date:8/19/2007

multiple myeloma, a population known to be at risk of this complication due to pre-existing renal changes. Until we know more about how to prevent the complication in this specific patient population, we have decided not to enroll further patients and will focus our resources onto the other ongoing studies in cancer indications where belinostat is demonstrating a therapeutic benefit. We have reported positive preliminary safety and efficacy data from three indications including single agent activity against peripheral T-cell lymphoma and cutaneous T-cell lymphoma, as well as the combination of IV belinostat with carboplatin and paclitaxel in the treatment of ovarian cancer. We are very excited about the activity reported in these indications, as we feel they represent potential registrational paths for belinostat and look forward to reporting updated results in the fourth quarter of 2007."

Belinostat in combination with carboplatin and paclitaxel against ovarian cancer:

To date, three partial responses (two confirmed, one unconfirmed) have been achieved in the 23 heavily pretreated patients with recurrent ovarian cancer enrolled, of which 14 patients remain on study with best response yet to be determined. The response rate observed in Stage I of the study design has triggered expansion of enrollment to a total of 32 patients in this Phase II Simon-Two stage design clinical trial in order to gain a better estimate of the objective response rate and duration of response. CuraGen anticipates presenting updated results during the fourth quarter of 2007.

Belinostat in combination with carboplatin and paclitaxel against bladder cancer:

Patient treatment was recently initiated in this Phase II open-label trial. A total of 15 patients with transitional cell cancer of the bladder will be enrolled to evaluate the safety and efficacy of intravenous belinostat in combination with carboplatin and paclitaxel.

Dr. Shannon further remarked, "We are e
'/>"/>

SOURCE CuraGen Corporation

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform

Post Your Comments:

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Developmen...(multiple myeloma a population known to b...),Health